Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 1:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 33 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Cystic Fibrosis, Pulmonary Disease, Chronic Obstructive
Interventions
Tobramycin solution for inhalation (TOBI), Oral placebo, Oral ciprofloxacin
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
1 Year to 12 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
54
States / cities
Birmingham, Alabama • Los Angeles, California • Oakland, California + 49 more
Conditions
Gonorrhea Male
Interventions
Cefixime, Ceftriaxone, Ciprofloxacin, Neisseria gonorrhoeae strain FA1090, Meningococcal Group B Vaccine, Influenza Vaccine, Tetanus-diptheria Vaccine
Drug · Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Urolithiasis, UTI
Interventions
Ciprofloxacin, trimethoprim/sulfamethoxazole, No Intervention
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
Not listed
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
San Diego, California
Conditions
Leukemia, Acute Myeloid Leukemia, Lymphoblastic Leukemia in Children
Interventions
Dalbavancin, Fluoroquinolone (either ciprofloxacin or levofloxacin at the discretion of the treating clinician)
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 25 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Memphis, Tennessee
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Peru-15-pCTB in Healthy Adult Subjects

NCT00654108
Conditions
Gastroenteritis Escherichia Coli
Interventions
Ciprofloxacin, Peru-15-pCTB, Sodium bicarbonate/Ascorbic Acid/Aspartame Buffer
Drug · Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Pneumonia, Bacterial, Community-Acquired Infections, Nosocomial Infection, Pneumonia, Ventilator-Associated
Interventions
Cefepime placebo, Cefepime, Doripenem, Doripenem placebo, Amoxicillin/clavulanate potassium
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
3 Months to 18 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Little Rock, Arkansas • Cleveland, Ohio • Toledo, Ohio + 1 more
Conditions
Fed
Interventions
CIPRO®XR
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years to 45 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Houston, Texas
Conditions
Urinary Tract Infections, Stress Urinary Incontinence, Urinary Incontinence
Interventions
Bactrim (800/160 mg), Keflex (500 mg), Cipro (250 mg), or Macrobid (100mg)
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Miami, Florida
Conditions
Fasting
Interventions
CIPRO®XR
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years to 45 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Houston, Texas
Conditions
Pharmacokinetics
Interventions
PrimeC 748 mg, Ciprofloxacin 750 MG, Celecoxib 200mg
Drug
Lead sponsor
NeuroSense Therapeutics Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Las Vegas, Nevada
Conditions
Appendicitis
Interventions
Cefoxitin, Ertapenem, Moxifloxacin, Tigecycline, Ticarcillin-Clavulanic Acid; Metronidazole plus Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, or Levofloxacin, Appendectomy
Drug · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
1,552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
25
States / cities
Sylmar, California • Torrance, California • Aurora, Colorado + 14 more
Conditions
Cystic Fibrosis, Chronic Bronchitis
Interventions
IV amikacin, PO azithromycin, IV ceftazidime, PO ciprofloxacin, IV meropenem, IV piperacillin-tazobactam, IV ticarcillin-clavulanate, IV tobramycin
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
14 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
8
States / cities
Iowa City, Iowa • St Louis, Missouri • Cincinnati, Ohio + 4 more
Completed Phase 1 Interventional Accepts healthy volunteers

Monoclonal Antibody for Treatment of Inhalation Anthrax

NCT00138411
Conditions
Bacillus Anthracis (Anthrax)
Interventions
Ciprofloxacin 500 mg, ETI-204 (Anthim)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Healthy
Interventions
Ciprofloxacin Extended-Release Tablets 1000 mg, Cipro® XR Tablets 1000 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Morgantown, West Virginia
Conditions
Healthy
Interventions
Ciprofloxacin Extended-Release Tablets 500 mg, Cipro® XR Tablets (500 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Morgantown, West Virginia
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Prophylactic Antibiotic Administration for Bladder OnabotulinumtoxinA Injection

NCT05719285
Conditions
Overactive Bladder, Overactive Bladder Syndrome, Urge Incontinence, Urinary Incontinence, Urge
Interventions
Single-Dose Antibiotic, Multi-Dose Antibiotic
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Gonococcal Infection
Interventions
Ciprofloxacin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
9
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 4 more
Conditions
Otorrhea, Otitis Media With Effusion in Children
Interventions
Otiprio, Ciprodex
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
6 Months to 10 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Experimental Human Infection With Neisseria Gonorrhoeae

NCT03840811
Conditions
Gonococcal Infection
Interventions
Cefixime, Ceftriaxone, Ciprofloxacin, Neisseria gonorrhoeae strain FA1090 A26, Neisseria gonorrhoeae strain FA7537
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 36 Years · Male only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Experimental Human Infection With Neisseria Gonorrhoeae (LptA Trial)

NCT04870138
Conditions
Gonococcal Infection
Interventions
Azithromycin, Ceftriaxone, Ciprofloxacin, Neisseria gonorrhoeae strain FA1090 A26, Neisseria gonorrhoeae strain FA7527
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 35 Years · Male only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Ciprofloxacin XR Drug Interaction Study With MMX® Mesalazine/Mesalamine

NCT01402947
Conditions
Healthy
Interventions
Ciprofloxacin XR + MMX Placebo, MMX Mesalazine/mesalamine + Ciprofloxacin XR
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Lenexa, Kansas
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Trial of Randomized Antibiotic Administration in Percutaneous Nephrolithotomy

NCT02579161
Conditions
Kidney Stones
Interventions
cephalosporins, Fluoroquinolones, Clindamycin, Ampicillin/Gentamicin
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
2
States / cities
Manhasset, New York • New Hyde Park, New York
Completed Phase 2 Interventional Results available

Dose Ranging Study of OTO-201 in AOMT

NCT02719158
Conditions
Acute Otitis Media, AOMT
Interventions
6 mg ciprofloxacin, 12 mg ciprofloxacin, Sham
Drug · Other
Lead sponsor
Otonomy, Inc.
Industry
Eligibility
6 Months to 17 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
San Diego, California
Completed Phase 1 Interventional Accepts healthy volunteers

Impact of Formulation on Ciprofloxacin Oral Absorption

NCT00992329
Conditions
Healthy
Interventions
ciprofloxacin
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland